A taxonomy of reasons for not prescribing guideline-recommended medications for patients with heart failure

https://doi.org/10.1016/S1543-5946(10)80007-8Get rights and content

Abstract

Background: Performance-measurement systems may work best when they account for the reasons why physicians do not provide guideline-recommended interventions.

Objective: This article develops a conceptual framework for understanding the proximate, patient-centered reasons why physicians do not prescribe angiotensin-converting enzyme (ACE) inhibitors or β-blockers to patients with heart failure and reduced systolic function.

Methods: This was a focus group study using a 2-stage design. Academically affiliated clinicians of different specialties and levels of training were recruited by e-mailed invitations sent to clinicians within each target group. To be included, candidates needed to be currently practicing in an ambulatory care setting in which they encountered patients with heart failure. In the first part of each group, participants were asked to describe reasons for not prescribing ACE inhibitors or â-blockers for patients with heart failure. Next, participants were asked to develop concept maps that organized these reasons into categories and described the relationships between these categories. The concept maps from each group were synthesized to develop a consensus scheme for categorizing reasons for nonprescribing.

Results: There were 31 participants in 7 focus groups; median age was 31 years and 55% (17/31) were women. Two broad themes emerged. First, clinicians hinted at their own attitude-related barriers to prescribing. However, they framed their comments largely in terms of patient-centered reasons for nonprescribing that arose in individual patient encounters. Second, decision making about heart failure drug therapy often involved a complex and overlapping series of considerations. Five categories of reasons for not prescribing ACE inhibitors or â-blockers emerged: (1) adverse effects of drug therapy; (2) nonadherence to therapeutic and monitoring plan; (3) patients' preferences and beliefs; (4) comanagement and transitions of care; and (5) prioritization and patient benefit.

Conclusions: Physicians' reasons for not prescribing guideline-recommended drugs for heart failure are complex but can be organized into a useful taxonomy. This taxonomy may be helpful for performance-measurement and quality-improvement programs that seek to understand reasons for physicians' nonadherence to guidelines.

References (37)

  • BA Bart et al.

    Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction

    Am J Cardiol

    (1997)
  • LC Walter et al.

    Cancer screening in elderly patients: A framework for individualized decision making

    JAMA

    (2001)
  • RA Hayward

    Performance measurement in search of a path

    N Engl J Med

    (2007)
  • EA Kerr et al.

    The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure

    Ann Intern Med

    (2008)
  • EA Kerr et al.

    Building a better quality measure: Are some patients with ‘poor quality’ actually getting good care?

    Med Care

    (2003)
  • SI Chaudhry et al.

    Do age and comorbidity affect intensity of pharmacological therapy for poorly controlled diabetes mellitus?

    J Am Geriatr Soc

    (2005)
  • JH Gurwitz et al.

    The ambiguous relation between aging and adverse drug reactions

    Ann Intern Med

    (1991)
  • DB Reuben

    Medical care for the final years of life: “When you're 83, it's not going to be 20 years”

    JAMA

    (2009)
  • MD Cabana et al.

    Why don't physicians follow clinical practice guidelines? A framework for improvement

    JAMA

    (1999)
  • AL Francke et al.

    Factors influencing the implementation of clinical guidelines for health care professionals: A systematic meta-review

    BMC Med Inform Decis Mak

    (2008)
  • B Carlsen et al.

    Thou shalt versus thou shalt not: A meta-synthesis of GPs' attitudes to clinical practice guidelines

    Br J Gen Pract

    (2007)
  • KA Foley et al.

    The impact of physician attitudes and beliefs on treatment decisions: Lipid therapy in high-risk patients

    Med Care

    (2006)
  • AC Freeman et al.

    Why general practitioners do not implement evidence: Qualitative study

    BMJ

    (2001)
  • C Kim et al.

    Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model

    J Gen Intern Med

    (2003)
  • SA Hunt et al.

    ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society

    Circulation

    (2005)
  • A Fuat et al.

    Barriers to accurate diagnosis and effective management of heart failure in primary care: Qualitative study

    BMJ

    (2003)
  • DA Redelmeier et al.

    Medical decision making in situations that offer multiple alternatives

    JAMA

    (1995)
  • E Ab et al.

    Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: A qualitative study

    BMC Fam Pract

    (2009)
  • Cited by (23)

    • Therapy modifications during hospitalization in patients with chronic heart failure

      2016, European Journal of Internal Medicine
      Citation Excerpt :

      A “treatment gap” might also occur in some of these patients, who are not treated despite being eligible [22]. Other possible reasons such as polypharmacy, age, or socio-medical reasons [12,14] could have also contributed to physicians' decisions but were not documented. Similar reasons could explain why not many of the patients reached target doses and why down-titration was common.

    View all citing articles on Scopus

    Presented at the American Geriatrics Society 2009 Annual Scientific Meeting, April 29–May 3, 2009, Chicago, Illinois; and the Society of General Internal Medicine 32nd Annual Meeting, May 13–16, 2009, Miami Beach, Florida.

    View full text